Tarhini, Ahmad A.
Moffitt Cancer Center
4 papers on CoChatORCID 0000-0002-3193-9702
Most cited papers
- Verified
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 394
- Verified
Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609
Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology
Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers
Cited by 184
- Verified
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 86
- Verified
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A. (2018) · Journal of Translational Medicine
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 51
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free